Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers

Annals of Oncology, Journal Year: 2024, Volume and Issue: 35(9), P. 792 - 804

Published: June 20, 2024

Hormone receptor expression is a known positive prognostic and predictive factor in breast cancer; however, limited evidence exists on its impact prognosis of young patients harboring pathogenic variant (PV) the BRCA1 and/or BRCA2 genes.

Language: Английский

---

Oxyresveratrol in Breast Cancer Cells: Synergistic Effect with Chemotherapeutics Doxorubicin or Melphalan on Proliferation, Cell Cycle Arrest, and Cell Death

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(7), P. 873 - 873

Published: June 29, 2024

Breast cancer is the second most common type of in world. Polyphenols can act at all stages carcinogenesis and oxyresveratrol (OXY) promising anticancer properties, mainly associated with chemotherapy drugs. The aim this study was to investigate effect OXY doxorubicin (DOX) or melphalan (MEL), either isolated associated, MCF-7 MDA-MB-231 breast cells. Our results showed that OXY, DOX, MEL presented cytotoxicity, addition altering cell morphology. synergistic association + DOX reduced viability a dose-dependent manner. associations were able alter ROS production, ∆Ψm, cycle; led cells necrosis. Furthermore, lead apoptosis upregulate caspases-3, -7, -8, -9 both LC-HRMS 7-deoxidoxorubicinone doxorubicinol, responsible for cardiotoxic effect, not identified treated association. In summary, our demonstrate first time chemotherapeutic agents cells, offering new strategy future animal studies.

Language: Английский

---

The Association between Early-Onset Diagnosis and Clinical Outcomes in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis

Cancers, Journal Year: 2023, Volume and Issue: 15(7), P. 1923 - 1923

Published: March 23, 2023

Early-onset diagnosis, defined by age <40 years, has historically been associated with inferior outcomes in breast cancer. Recent evidence suggests that this association is modified molecular subtype. We performed a systematic review and meta-analysis of the literature to synthesize on between early-onset diagnosis clinical triple-negative cancer (TNBC). Studies comparing risk non-metastatic TNBC patients later-onset (≥40 years) were queried Medline EMBASE from inception February 2023. Separate meta-analyses for specific survival (BCSS), overall (OS), disease-free (DFS), locoregional recurrence-free (LRRFS), distant (DRFS), pathological complete response (pCR). In total, 7581 unique records identified, 36 studies satisfied inclusion criteria. The pooled any recurrence was significantly greater compared patients. Better BCSS OS observed relative aged >60 years. odds achieving pCR higher Future should evaluate role management implementation novel therapies such as PARP inhibitors real-world settings, whether they improve outcomes.

Language: Английский

---

Matrine Inhibits Breast Cancer Cell Proliferation and Epithelial-Mesenchymal Transition Through Regulating the LINC01116/miR-9-5p/ITGB1 Axis

Balkan Medical Journal, Journal Year: 2025, Volume and Issue: 42(1), P. 54 - 65

Published: Jan. 3, 2025

Background: Breast cancer (BC) is the most prevalent solid affecting women's health globally.Matrine (MAT), a traditional Chinese herb, has exhibited antitumor effects against BC.However, its mechanism of action, particularly whether it involves control cell proliferation and epithelial-mesenchymal transition (EMT), remains unknown. Aims:To explore MAT's role in BC regulatory mechanisms, as well to identify targets for development novel medicines improvement treatment modalities.Study Design: Experimental study. Methods:The UALCAN Lnc2Cancer 3.0 databases were used predict expression LINC01116 BC.The cells (MDA-MB-231 MCF-7) treated with various concentrations MAT, optimal dose timing MAT action determined using CCK-8 quantitative real-time polymerase chain reaction assays.Functional assays such CCK-8, EdU, Transwell, Western blot, flow cytometry performed on cells, impacts LINC01116, miR-9-5p, ITGB1 levels assessed.The association between was evaluated dual luciferase RNA immunoprecipitation assays.Furthermore, size weight subcutaneous tumors mice model effect overexpression vivo histopathological staining (TUNEL immunofluorescence, hematoxylin & eosin staining, immunohistochemistry Ki67 Bax) also assessed. Results:The duration administration 8 µm 24 h, respectively.MAT effectively inhibited proliferation, EMT progression, biological functions, while promoting apoptosis.The animal experiments demonstrated that tumor growth vivo.Furthermore, which acted sponge increasing level.

Language: Английский

---

Evaluating PREDICT and developing outcome prediction models in early-onset breast cancer using data from Alberta, Canada

Breast Cancer Research and Treatment, Journal Year: 2025, Volume and Issue: unknown

Published: March 12, 2025

Abstract Introduction Outcome prediction research in early-onset breast cancer (EoBC) is limited. This study evaluated the predictive performance of NHS PREDICT v2.1 and developed two models for 5-year 10-year all-cause mortality a cohort EoBC patients Alberta, Canada. Methods Adults < 40 years diagnosed with invasive Canada from 2004 to 2020 were included. Patient data entered into estimates at 5 10 extracted. Two mortality: multivariable Cox regression LASSO penalization (LASSO Cox) random survival forests (RSF). Internal validation was performed using nested tenfold cross-validation repeated 200 times. Model assessed receiver operator characteristic calibration curves years. Results In total, 1827 eligible inclusion. At years, had an area under curve 0.78 (95%CI 0.74–0.82) overestimated by 2.4% 0.70–4.33) overall cohort. No differences observed predicted The model showed better discrimination than RSF model, but both poor underestimated mortality. Conclusion tended overestimate those > 30% risks 50% We did not identify additional that would be clinically useful applying machine learning. More follow-up emerging systemic treatment variables are required outcome modern cohorts.

Language: Английский

---

Age, Body Mass Index, Tumor Subtype, and Racial and Ethnic Disparities in Breast Cancer Survival

JAMA Network Open, Journal Year: 2023, Volume and Issue: 6(10), P. e2339584 - e2339584

Published: Oct. 25, 2023

Black women in the United States have higher breast cancer (BC) mortality rates than White women. The combined role of multiple factors, including body mass index (BMI), age, and tumor subtype, remains unclear.To assess association race ethnicity with survival among clinical trial participants early-stage BC (eBC) according to BMI.This cohort study analyzed data, as November 12, 2021, from enrolled between 1997 2010 4 randomized adjuvant chemotherapy trials: Cancer Leukemia Group B (CALGB) 9741, 49907, 40101 well North Central Treatment (NCCTG) N9831, legacy groups Alliance Clinical Trials Oncology. Median follow-up was 9.8 years.Non-Hispanic Hispanic were compared non-Hispanic within subgroups subtype (hormone receptor positive [HR+]/ERBB2 [formerly HER2] negative [ERBB2-], ERBB2+, HR-/ERBB2-), age (<50, 50 <65, ≥65 years), BMI (<18.5, 18.5 <25.0, 25.0 <30.0, ≥30.0).Recurrence-free (RFS) overall (OS).Of 9479 participants, 436 (4.4%) Hispanic, 871 (8.8%) Black, 7889 (79.5%) White. median (range) 52 (19.0-89.7) years. Among HR+/ERBB2- tumors, individuals had worse RFS (hazard ratio [HR], 1.49; 95% CI, 1.04-2.12; 5-year RFS, 88.5% vs 93.2%) individuals, although global test for not significant any subtype. There no OS differences by Race associated young (age <50 years; P = .008); (HR, 1.34; 1.04-1.71; OS, 86.6% 92.0%) 1.62; 1.16-2.29; 86.2% participants. BMIs 25 less 30, having 1.81; 1.23-2.68; 83.2% 87.3%) participants.In this study, racial ethnic disparities identified patients eBC receiving standardized initial care, potentially at-risk subgroups, whom focused interventions may improve outcomes, found.

Language: Английский

---

Profile and clinical significance of SPARCL1 and its prognostic significance in breast cancer

Oncology Letters, Journal Year: 2025, Volume and Issue: 29(4), P. 1 - 13

Published: Feb. 24, 2025

Secreted protein acidic and cysteine-rich like 1 (SPARCL1; also known as MAST9) exhibits low expression levels in several malignant tumors is positively associated with tumor growth poor prognosis. Furthermore, there may be an association between SPARCL1 breast cancer; however, further comprehensive research necessary. The present study assessed the relationship cancer using RNA sequencing clinical data from Cancer Genome Atlas database (including mutations, immune infiltration prognosis data), cell experiments samples. findings indicated that was significantly lower tissues compared other tumors, its downregulation negatively overall survival rate of patients. Moreover, analysis receiver operator characteristic curve analysis, univariate multivariate Cox regression models suggested has potential a diagnostic biomarker for detection. Additionally, demonstrated to degree infiltration, whilst functional enrichment revealed involvement key areas such cycle regulation, protein/ATP binding processes, cellular aging mechanisms, oocyte meiosis pathways DNA replication processes. Overall, results highlight how big mining combined experimental verification can provide insights into role pathogenesis disease. However, investigations are warranted validate these more understanding implications therapy patients cancer.

Language: Английский

---

Temporal trend of breast cancer burden among younger and older Brazilian women, 1990–2019

Revista Brasileira de Epidemiologia, Journal Year: 2025, Volume and Issue: 28

Published: Jan. 1, 2025

To analyze the temporal trend of burden breast cancer in Brazilian women under 40 years age compared to group over age, between 1996 and 2019. An ecological time study was conducted Brazil 2019 using data from Global Burden Disease (GBD) study. The segmented regression method (Joinpoint Regression) applied rates among age. capture differences level mortality DALYs, rate ratio calculated for two groups on a year-by-year basis. Regarding DALY, an average annual decline 0.7% (95%CI -0.8 -0.5, p<0.01) observed old, while increase 1.0% 0.9 1.1, p<0.001) noted up old. For mortality, older 0.3% per year -0.4 -0.2, p<0.001), young 0.8% 0.7 1.0, p<0.001). DAILY 5.2, 8.1. analysis reinforces idea that magnitude is health issue requiring attention decision-makers. This diagnosis underscores importance initiating discussions need review population screening criteria, incorporating clinical prediction rules.

Language: Английский

---

Primary endocrine therapy can be effective in decreasing lymph node burden in hormone receptor positive breast cancers

South African Journal of Surgery, Journal Year: 2025, Volume and Issue: 63(1), P. 1 - 4

Published: March 1, 2025

Breast cancer is a significant global health concern. Primary endocrine therapy (PET) and primary chemotherapy (PCT) are employed to manage hormone receptor positive breast cancers in the neoadjuvant setting. We hypothesise that PET as effective treat axillary metastases. All patients treated for at Tygerberg Hospital Unit during period of 2016-2019 were included. Patients who did not receive PCT or excluded, undergo lymph node dissection (ALND). The sample consisted 176 patients. median age was 49.2 years (IQR = 42.4-57.9 years; range 25.1-84.6 years), 174/176 (98.9%) female. Of patients, 35/176 (19.9%) had luminal A cancers, while 141/176 (80.1%) B cancers. Among these 150/176 (85.2%) underwent 26/176 (14.8%) received PET. burdens found via ALND similar (median 25.0%; IQR 0.0-50.0%) 16.8%; 0.0-89.0%; p 0.66). rates with no nodal involvement also (47/150 31.3%) (9/26 34.6%; 0.74). Multivariate analysis showed there confounding effects due age, sex, HIV status, molecular subtype AJCC stage. Our study statistically difference burden regardless whether given cancer.

Language: Английский

---

How to Preserve Fertility in Reproductive-Age Women with Cancer

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(6), P. 1912 - 1912

Published: March 12, 2025

Chemotherapy and radiotherapy, among other gonadotoxic treatments, can significantly affect ovarian reserve function, potentially leading to premature insufficiency (POI) sterility. With the increasing survival rates young female cancer patients, fertility preservation (FP) has become an essential aspect of care. The decision pursue FP depends on various factors, including patient age, reserve, type treatment, its potential. Several strategies are available, oocyte, embryo, tissue cryopreservation. While oocyte embryo cryopreservation gold standard techniques, in vitro maturation (IVM) present viable alternatives for patients who cannot undergo stimulation or whom is contraindicated. Despite significant advances within practice, challenges remain ensuring timely counseling, equitable access services, optimizing long-term reproductive outcomes. Continued research needed refine existing explore innovative approaches, address ethical considerations decision-making. This review explores current options, their clinical applications, future directions improve outcomes women undergoing treatments.

Language: Английский

---